GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LadRx Corp (OTCPK:LADX) » Definitions » Enterprise Value
中文

LadRx (LADX) Enterprise Value : $-0.99 Mil (As of Apr. 25, 2024)


View and export this data going back to 1986. Start your Free Trial

What is LadRx Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, LadRx's Enterprise Value is $-0.99 Mil. LadRx's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.82 Mil. Therefore, LadRx's EV-to-EBIT ratio for today is 0.26.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, LadRx's Enterprise Value is $-0.99 Mil. LadRx's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.77 Mil. Therefore, LadRx's EV-to-EBITDA ratio for today is 0.26.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, LadRx's Enterprise Value is $-0.99 Mil. LadRx's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Therefore, LadRx's EV-to-Revenue ratio for today is .


LadRx Enterprise Value Historical Data

The historical data trend for LadRx's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LadRx Enterprise Value Chart

LadRx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.37 54.43 17.25 5.38 -1.39

LadRx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.38 4.01 -2.31 -2.06 -1.39

Competitive Comparison of LadRx's Enterprise Value

For the Biotechnology subindustry, LadRx's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LadRx's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LadRx's Enterprise Value distribution charts can be found below:

* The bar in red indicates where LadRx's Enterprise Value falls into.



LadRx Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

LadRx's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

LadRx's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LadRx  (OTCPK:LADX) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

LadRx's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-0.987/-3.824
=0.26

LadRx's current Enterprise Value is $-0.99 Mil.
LadRx's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.82 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

LadRx's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=-0.987/-3.766
=0.26

LadRx's current Enterprise Value is $-0.99 Mil.
LadRx's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.77 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

LadRx's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=-0.987/0
=

LadRx's current Enterprise Value is $-0.99 Mil.
LadRx's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LadRx Enterprise Value Related Terms

Thank you for viewing the detailed overview of LadRx's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


LadRx (LADX) Business Description

Traded in Other Exchanges
N/A
Address
11726 San Vicente Boulevard, Suite 650, Los Angeles, CA, USA, 90049
LadRx Corp operates as a biopharmaceutical research and development company in the healthcare sector of the United States. It is focused on the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company develops Aldoxorubicin, which is meant to cure soft tissue sarcoma, a kind of tumor. It also develops Arimoclomol which is in development in Niemann Pick disease Type C (NPC) and Gaucher disease.
Executives
Cary J Claiborne director 3056 SENECA CHIEF TRAIL, ELLICOTT CITY MD 21042
Stephen Snowdy officer: Chief Executive Officer C/O CYTRX CORPORATION, 11726 SAN VICENTE BOULEVARD, SUITE 650, LOS ANGELES CA 90049
Jennifer K. Simpson director C/O DELCATH SYSTEMS, INC., 810 SEVENTH AVENUE, SUITE 3505, NEW YORK NY 10019
Eric Curtis officer: Pres., Chief Operating Officer ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
Felix Kratz officer: Vice President Drug Discovery 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Joel K Caldwell director 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Chawla Shanta M.d. officer: Senior VP-Drug Development 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Earl W Brien director 11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES CA 90049
Olivia C Ware officer: Chief Commercial Officer 11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES CA 90049
Cheryl Cohen director C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105
Eric Jay Selter director 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Anita J Chawla director 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Joseph Rubinfeld director C/O SUPERGEN INC, 4140 DUBLIN BLVD STE 200, DUBLIN CA 94568
Douglas Scott Wieland officer: Sr VP - Drug Development 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Louis Ignarro director 11726 SAN VICENTE BLVD, STE 650, LOS ANGELES CA 90049

LadRx (LADX) Headlines

From GuruFocus

CytRx Corporation Reports Second Quarter 2019 Financial Results

By PRNewswire PRNewswire 08-09-2019

CytRx Corporation to Commence Trading on OTCQB Venture Market

By PRNewswire PRNewswire 05-31-2019

CytRx Corporation to Present at the 2018 MicroCap Conference

By PRNewswire PRNewswire 09-25-2018